Poliovirus vaccine inactivated (human diploid cell) - Biologic Drug Details

Summary for poliovirus vaccine inactivated (human diploid cell)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for poliovirus vaccine inactivated (human diploid cell) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for poliovirus vaccine inactivated (human diploid cell) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for poliovirus vaccine inactivated (human diploid cell) Derived from Patent Text Search

No patents found based on company disclosures

Poliovirus vaccine inactivated (human diploid cell) Market Analysis and Financial Projection Experimental

Global Inactivated Poliovirus Vaccine Market: Dynamics and Financial Trajectory

Market Overview

The global inactivated poliovirus vaccine (IPV) market is a critical segment in the fight against polio, a highly infectious disease that can cause paralysis and even death. Here, we delve into the market dynamics, financial trajectory, and key factors influencing the growth of this vital vaccine.

Current Market Size and Growth Potential

As of 2022, the global inactivated poliovirus vaccine market was valued at USD 715 million. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% during the forecast period from 2023 to 2030[1][3].

Driving Factors for Growth

Several factors are driving the growth of the IPV market:

• Increased Awareness and Vaccination Programs: Rising awareness about the importance of vaccination and the ongoing efforts to eradicate polio globally are significant drivers. Governments and international organizations are investing heavily in vaccination programs, which boosts the demand for IPV[1][3].
• Government Initiatives: Enhanced government initiatives and special programs aimed at improving healthcare facilities, particularly in regions like the Asia-Pacific, are contributing to market growth[1].
• Technological Advancements: The development of new vaccine technologies, such as the use of attenuated Sabin strains instead of wild-type Salk polio strains, enhances safety and efficiency in vaccine production[4].

Market Segmentation

By Type

The IPV market is segmented into two main types based on the cell culture used:

• Human Diploid Cell: This segment currently holds the largest market share. Human diploid cells are widely used due to their reliability and safety profile[1][3].
• Monkey Kidney Cell: Although the human diploid cell segment is dominant, the monkey kidney cell segment is expected to grow at a higher CAGR due to its cost-effectiveness and ability to produce large quantities of viruses economically[1].

By Distribution Channel

The market is also segmented based on distribution channels:

• Public Distribution: Held a significant share in 2022, public distribution channels play a crucial role in national immunization programs and campaigns[1][3].
• Private Distribution: Includes private healthcare providers, pharmacies, and other channels. This segment is growing as private healthcare services expand globally[3].
• Non-profit Organizations: International organizations and NGOs are key players in distributing IPV, especially in regions with limited healthcare infrastructure[3].

By Geography

The market is analyzed across various regions:

• North America: Includes the U.S. and Canada, where IPV is part of routine childhood immunization schedules[3].
• Europe: Widely used for polio eradication efforts and routine vaccination[3].
• Asia-Pacific: Expected to grow with a high CAGR due to ongoing polio cases and vaccination efforts in countries like India, China, and Japan[1].
• Latin America, Middle East, and Africa: These regions face challenges such as conflict, infrastructure issues, and vaccine hesitancy, but are also key areas for polio eradication efforts[3].

Challenges and Limitations

Despite the growth potential, the IPV market faces several challenges:

• High Production Costs: The intricate procedures and strict quality control standards required for IPV production drive up costs, making it less accessible in low-income areas[3].
• Regulatory Difficulties: Stringent and varied regulatory norms across different regions can delay the entry of new IPV producers or variants into the market[3].
• Complexity of Immunization Programs: Coordinating healthcare providers, legislators, and communities to implement comprehensive immunization programs is complex and can hinder broad IPV penetration[3].

Key Players

The market is dominated by several major players:

• GlaxoSmithKline
• Sanofi
• Astellas Pharma
• Serum Institute of India Pvt. Ltd.
• Kedrion Biopharma
• Pfizer Inc.
• Bio Farma
• Sinovac Biotech Ltd.
• Cadila Healthcare Limited
• LG Chem Ltd.[3]

Technological Advancements and Future Trends

Use of Attenuated Sabin Strains

The development of Sabin-IPV is a significant advancement. Using attenuated Sabin strains instead of wild-type Salk polio strains enhances safety during vaccine production and is critical for the post-OPV cessation period as part of the WHO's polio eradication strategy[4].

Technology Transfer

Efforts are underway to transfer IPV production technology to vaccine manufacturers in low and middle-income countries. This includes process development, optimization, and formulation research to reduce the cost per dose and prepare for large-scale production[4].

Regional Focus and Polio Eradication Efforts

Asia-Pacific Region

The Asia-Pacific region is a focal point for polio eradication efforts. Despite the virus being confined to only two countries (Afghanistan and Pakistan) as of 2021, ongoing vaccination campaigns are crucial. The region's growth in healthcare infrastructure and government initiatives are driving the demand for IPV[1].

Global Eradication Efforts

The global polio eradication initiative has significantly reduced the risk of wild poliovirus reintroduction in many regions. This has shifted the focus towards using IPV for individual protection without the risk of vaccine-associated paralytic poliomyelitis (VAPP)[2].

Financial Trajectory

The financial trajectory of the IPV market is positive, with a projected growth from USD 715 million in 2022 to USD 14.07 billion by 2031, at a CAGR of 5.1% during the forecast period 2024-2031[3].

Key Takeaways

• The global IPV market is growing due to increased awareness, government initiatives, and technological advancements.
• The monkey kidney cell segment is expected to grow at a higher CAGR due to its economic viability.
• Asia-Pacific is a key region for growth due to ongoing polio cases and vaccination efforts.
• High production costs and regulatory difficulties are significant challenges.
• Major players are investing in technology transfer and process optimization to reduce costs and enhance safety.

Frequently Asked Questions

Q1: What is the current market size of the global inactivated poliovirus vaccine market?

The global inactivated poliovirus vaccine market was valued at USD 715 million in 2022[1].

Q2: What is the expected growth rate of the global IPV market?

The market is expected to grow at a CAGR of 5.1% during the forecast period from 2023 to 2030[1][3].

Q3: Which segment has the largest market share by type in the IPV market?

The human diploid cell segment currently holds the largest market share by type[1].

Q4: What are the main challenges facing the IPV market?

High production costs, regulatory difficulties, and the complexity of immunization programs are significant challenges[3].

Q5: Which region is expected to grow at a higher CAGR in the IPV market?

The Asia-Pacific region is expected to grow at a higher CAGR due to ongoing polio cases and vaccination efforts[1].

Cited Sources

1. UnivDatos: Global Inactivated Poliovirus Vaccine Market Analysis & Forecast (2023-2030)[1].
2. CDC: Introduction of A Sequential Vaccination Schedule of Inactivated Poliovirus Vaccine[2].
3. Verified Market Research: Inactivated Poliovirus Vaccine Market Size, Forecast[3].
4. PubMed: Inactivated polio vaccine development for technology transfer using attenuated Sabin strains[4].